Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor
cells has been implicated in triggering a complex signal cascade that leads to increased …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

Introduction: The standard of care for patients with locally-advanced head and neck cancer
is chemoradiation or surgical resection followed by radiation treatment with or without …

The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …

The integration of targeted therapies into clinical practice constitutes the paradigm of
oncology treatment in the current era. Cetuximab, a recombinant human/mouse chimeric …

With its targeted mechanism of action and synergistic activity with current treatment
modalities, cetuximab is a potentially valuable treatment option for patients with recurrent …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor
receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In …

Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …